Top Healthcare Stocks in Citigroup’s Q3 Portfolio

Wall St. Watchdog reveals information regarding Citigroup’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 321 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $1.777 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Citigroup reported holding 4,033,370 shares with a market value of $268,299,759. This comprised 0.61% of the total portfolio. On 09/30/2011, Citigroup reported holding 3,889,137 shares with a market value of $247,699,130. This comprised 0.65% of the total portfolio. The net change in shares for this position over the two quarters is -144,233. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Citigroup reported holding 9,690,178 shares with a market value of $199,617,670. This comprised 0.45% of the total portfolio. On 09/30/2011, Citigroup reported holding 10,401,127 shares with a market value of $183,891,929. This comprised 0.49% of the total portfolio. The net change in shares for this position over the two quarters is 710,949. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Citigroup reported holding 3,767,034 shares with a market value of $132,938,633. This comprised 0.3% of the total portfolio. On 09/30/2011, Citigroup reported holding 3,899,517 shares with a market value of $127,514,209. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is 132,483. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Citigroup reported holding 3,112,652 shares with a market value of $90,142,399. This comprised 0.2% of the total portfolio. On 09/30/2011, Citigroup reported holding 3,008,003 shares with a market value of $94,391,132. This comprised 0.25% of the total portfolio. The net change in shares for this position over the two quarters is -104,649. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Novartis Ag (NYSE:NVS): On 06/30/2011, Citigroup reported holding 965,317 shares with a market value of $58,990,522. This comprised 0.13% of the total portfolio. On 09/30/2011, Citigroup reported holding 1,434,774 shares with a market value of $80,017,347. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is 469,457. About Company: Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Citigroup reported holding 1,470,351 shares with a market value of $85,794,979. This comprised 0.19% of the total portfolio. On 09/30/2011, Citigroup reported holding 1,328,487 shares with a market value of $73,013,644. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -141,864. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Citigroup reported holding 1,432,360 shares with a market value of $73,881,131. This comprised 0.17% of the total portfolio. On 09/30/2011, Citigroup reported holding 1,395,328 shares with a market value of $64,352,526. This comprised 0.17% of the total portfolio. The net change in shares for this position over the two quarters is -37,032. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Citigroup reported holding 1,350,358 shares with a market value of $50,678,934. This comprised 0.11% of the total portfolio. On 09/30/2011, Citigroup reported holding 1,586,150 shares with a market value of $58,639,967. This comprised 0.15% of the total portfolio. The net change in shares for this position over the two quarters is 235,792. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Glaxosmithkline Plc (NYSE:GSK): On 06/30/2011, Citigroup reported holding 173,118 shares with a market value of $7,426,762. This comprised 0.02% of the total portfolio. On 09/30/2011, Citigroup reported holding 1,320,505 shares with a market value of $54,523,653. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is 1,147,387. About Company: GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders
  • Cephalon Inc. (NASDAQ:CEPH): On 06/30/2011, Citigroup reported holding 519,709 shares with a market value of $41,524,750. This comprised 0.09% of the total portfolio. On 09/30/2011, Citigroup reported holding 642,165 shares with a market value of $51,822,714. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is 122,456. About Company: Cephalon, Inc. is an international biopharmaceutical company that discovers, develops, and markets biopharmaceutical products to treat neurological disorders, pain, and cancer. The Company’s products include a product that treats excessive daytime sleepiness associated with narcolepsy.

(Note: Data regarding Citigroup’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>